Home | Life Sciences Intellectual Property Review
WEB1 day ago · Dexcom suffers second patent revocation at hands of UPC. The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills. Unified Patent Court.
Latest News & Features | Life Sciences Intellectual Property Review
WEBSep 19, 2024 · Dexcom suffers second patent revocation at hands of UPC. The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills. 17 September 2024. Biotechnology.
Americas | Life Sciences Intellectual Property Review
WEB13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.
CRISPR | Life Sciences Intellectual Property Review
WEB9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
'This is a big problem’: The CRISPR controversy and the ‘mess’ at …
WEB1 day ago · A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight.
Unified Patent Court | Life Sciences Intellectual Property Review
WEB12 December 2023 Hearing is latest in dispute between the biotech research firms | Multi-jurisdictional case concerns patents relating to the in-situ detection of analytes. 28 November 2023 UPC judge, EPO director and Regeneron counsel shed light on the court’s dynamics at London event | Life sciences sector emerging as a major player in the ...
Biotechnology | Life Sciences Intellectual Property Review
WEB4 July 2024 UK leg of global litigation over mRNA tech sees patents ruled valid and invalid | Justice Meade follows EPO in decision on Moderna’s EP 565 patent | Pfizer and German partner BioNTech on the hook for EP 949 | Opinion on …
Generics | Life Sciences Intellectual Property Review
WEBThe pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP. 28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions ...
Interview: Klaus Grabinski, UPC Court of Appeal president
WEB4 days ago · 9 September 2024 UPC clarifies that evidence must show that pre-launch preparations are complete for threat of imminent infringement to occur | Question remains over how the UPC will deal with the cumulative activities of several companies in a group | Court also broaches key cross-border question.
Magazine Archive | Life Sciences Intellectual Property Review
WEBMagazine Archive. Click the thumbnails below to view the Life Sciences IP Review magazines. LSIPR Spring/Summer 2022. Spring is here and the UK government is marking it by airing its Genetic Technology (Precision Breeding) Bill, promising to breathe new life into an area apparently suffocated by EU red tape. LSIPR new recruit Sarah Speight asks ...
Skip to content